ContentsPage 14 – How statistical and data analysis can support research innovations in rare diseasesPhastar tells Pharmafocus how data can be used to improve research innovations in rare diseasesPage 16 – Indication-based agreements – Akey enabler of UK access to combination therapies in oncologyJonathan Bowen considers the use of indication-based agreements to remove barriers to patient access to combination cancer therapiesPage 19 – Seven ways to boost HCP engagement through field behavioural changeVeeva explains the best ways that biopharma companies can boost their engagementPage 20 – Why are so many community pharmacies closing and what does this mean for local communities?Betsy Goodfellow considers why community pharmacies are closing and how this will impact the general publicTop NewsPage 4 Contaminated cough syrup leads to WHO Medical Product AlertPage 6First official long COVID-19 treatment could emerge from the NIH’s RECOVER initiativePage 8 – Jemperli by GSK approved to treat endometrial cancerPage 10American Heart Association grants $2.1m for research into possible link between CVD, migraines and strokesPage 12Rare disease treatments to be researched in partnership between Pfizer and AstraZeneca’s AlexionOur TeamExecutive Director
– PMGroup Worldwide Ltd
Karl Equi
Group Managing Editor
Iona Everson
ieverson@pmlive.comEditorial Assistants
Betsy Goodfellow
Sales Manager
Eliot Haynes
eliot@pharmafile.comDesign & Layout
Peter May
Pharmafocus is published by:Samedan Ltd
Suite E, 11 Bell Yard Mews,
175 Bermondsey Street,
London, SE1 3TN
Tel: +44 (0)20 7724 3456
Fax: +44 (0)20 7403 7747
www.pharmafile.comSubscriptions & Data ManagementCurwood CMS Tel: 01580 883840enquiries@c-cms.comISSN: 1465-5403
Pharmafocus is sent free of charge to selected permanent employees of ethical and OTC pharmaceutical and biotech companies. Employees are specifiers from middle and senior management with responsibility for making buying decisions. Selection is at the discretion of the Publisher. Copies are also available on a subscription basis at an annual fee of £115 (UK), £145 (Europe) and £185 (RoW).All subscriptions payable to Samedan. Back copies can be purchased for £15.00 each. Pharmafocus is published by Samedan Ltd. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form without permission, unless for the purposes of reference and comment.©2022 Samedan Ltd, Pharmaceutical PublishersThe opinions and views expressed by contributors to this publication are not necessarily those of the Editor or the Publisher and, while every care has been taken in the preparation of the newspaper, the Editor and the Publisher are not responsible for such opinions and views, or for any inaccuracies in the articles. The Publisher is not responsible for any images supplied by contributors. While every care is taken with artwork supplied, the Publisher cannot be held responsible for any loss or damage incurred. The entire content of this publication is protected by copyright. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form, by any means – electronic, mechanical, photocopying or otherwise – without the prior permission of the Publisher.